Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) (Q58024747)
Jump to navigation
Jump to search
article by J. R. Infante et al published 20 June 2011 in Journal of Clinical Oncology
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) |
article by J. R. Infante et al published 20 June 2011 in Journal of Clinical Oncology |
Statements
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) (English)
0 references
20 June 2011
0 references
29
0 references
18_suppl
0 references
CRA8503-CRA8503
0 references